Roslyn A. Wallace
305 Grattan St
Melbourne, VIC 3000, Australia
Melbourne, VIC 3000, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.
Journal: Nature communications
Published: November 21, 2025
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.
Journal: The Lancet. Oncology
Published: October 07, 2025
Increased Thyroidal Activity on Routine FDG-PET/CT after Combination Immune Checkpoint Inhibition: Temporal Associations with Clinical and Biochemical Thyroiditis.
Journal: Cancers
Published: October 24, 2023
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
Journal: Journal of translational medicine
Published: October 06, 2023
Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
Journal: Frontiers in endocrinology
Published: September 17, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 27, 2023
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.
Journal: Journal for immunotherapy of cancer
Published: April 14, 2022
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 01, 2020
FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 26, 2020
Last Updated: 09/26/2026